Viking Files 424B5 for Convertible Notes Tranche of $400M Concurrent Offering
VKTX sits 55% above its 52-week low of $24.78 on elevated volume (5.0× avg).
Summary
Viking Therapeutics filed the prospectus supplement for the convertible senior notes tranche of its $400 million concurrent offering, providing definitive terms for notes due 2032 alongside a concurrent common stock offering.
Key Events · Financing and Capital Events · VKTX
-
Convertible Notes Offering Formalized
Viking filed a 424B5 prospectus supplement for convertible senior notes due 2032, part of a $400 million concurrent offering announced earlier today. The notes are senior unsecured obligations, convertible at a premium to the $40.85 last reported sale price on September 22, 2026.
-
Concurrent Common Stock Offering
The filing confirms a concurrent common stock offering of equal size is being conducted under a separate prospectus supplement. Neither offering is contingent on the other, so Viking may receive proceeds from one, both, or neither.
-
Capital Structure Impact
As of June 30, 2026, Viking had no consolidated indebtedness for borrowed money. The notes will be structurally subordinated to approximately $79.8 million of subsidiary liabilities, and the indenture contains no financial covenants.
-
Use of Proceeds
Net proceeds from both offerings will fund continued clinical development of VK2735 and VK3019, plus general R&D, working capital, and potential acquisitions. The company reported $125.75 million in cash as of June 30, 2026.
Analysis · VKTX · Life Sciences
Viking Therapeutics is formalizing the convertible senior notes portion of its $400 million concurrent offering, announced earlier today. The 424B5 provides the definitive terms: notes due 2032, senior unsecured ranking, conversion at a premium to the $40.85 last reported sale price, and a concurrent common stock offering of equal size. The company is capitalizing on a strong stock price and positive Phase 2 maintenance data for VK2735 to fund its obesity pipeline. The notes are structurally subordinated to subsidiary liabilities, and the company had no consolidated debt as of June 30, 2026, so this is a significant new capital structure event.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VKTX was trading at $38.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $24.78 to $43.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.